Celgene Corporation will acquire privately held Gloucester Pharmaceuticals for $340 million in cash and as much as $300 million in milestone payments. The acquisition is intended to strengthen Celgene’s position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers. Gloucester develops new therapies that address the unmet medical needs in the treatment of cancer, including cutaneous T-cell lymphoma (CTCL), perip...